YH32364 Trial Targets EGFR Overexpressing Solid Tumors in Advanced Cancer Patients
A clinical trial is underway to evaluate the efficacy of YH32364 in patients with locally advanced or metastatic EGFR overexpressing solid tumors.
Asset / Drug
Drug and asset intelligence for YH32364 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
EGFR Inhibitor
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.